BioMarin Pharmaceutical — May 4, 2026 release

Updated 2026 Full-Year Financial Guidance (in millions, except EPS amounts) • Updated guidance reflects post-close contributions from Amicus beginning April 27, 2026. • As previously communicated, the acquisition of Amicus is expected to be slightly dilutive to full-year 2026 Non‑GAAP Diluted EPS; historical BioMarin Non-GAAP Diluted EPS guidance is unchanged. • The Amicus acquisition will be accounted for as a business combination, which will result in intangible amortization impacting GAAP results over future periods and excluded from Non‑GAAP results. BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non‑GAAP financial results. Guidance is subject to change based on various factors including finalization of purchase accounting. • The company expects approximately two-thirds of 2026 Non-GAAP Diluted EPS to be recognized in the second half of 2026, primarily due to the anticipated timing of revenue (more than 55% of 2026 Total Revenues is expected in 2H). Non-GAAP Diluted EPS in Q2 is expected to be modestly higher than in Q1. Item Provided on February 23, 2026 Updated May 4, 2026 Total Revenues $3,325 to $3,425 $3,825 to $3,925 Enzyme Therapies $2,225 to $2,275 $2,725 to $2,775 VOXZOGO $975 to $1,025 Unchanged Other Revenues (1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.95 to $5.15 $4.85 to $5.05 (1)    Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer